Skip to content
MARKETS / NASDAQ / CLPT
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

ClearPoint Neuro, Inc. CLPT

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$37.0M
▲ 17.8% YoY
$-25.5M
$-24.4M
In brief

What this company does

Its business consists of two integrated components: (i) a business providing medical devices for neurosurgical applications, and (ii) a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. As of March 6, 2026, ClearPoint Neuro had 172 full-time employees, including the 37 employees who joined in connection with the IRRAS acquisition.

Written from the business description in ClearPoint Neuro, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 17 March 2026. Every sentence was checked against that document before publication.

Growth
USD 37.0M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 37.0 · Net income -25.5
20M-10M-20M201020122014201620182020202220242025
Compound annual growth
+21.6%
+23.6%
+23.2%
+19.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +23.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−69 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -65.4% · Net -69.1%
-100%-200%-300%201020122014201620182020202220242025
ROE
FY2025 · ROE -95.6%
-100%-200%201020122014201620182020202220242025

Each USD of equity lost 96 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -24.4
-10M-20M201020122014201620182020202220242025

Total assetsUSD 97.7M
EquityUSD 28.0M
CashUSD 45.9M
Gross debtUSD 49.1M
Net debtUSD 3.2M
Current ratio5.91×

Net debt stands at 11% of equity.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0·····0.00.00.0··
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.90−0.70−0.90−0.68−0.69−0.43−0.42−0.56−0.93−2.93−4.48−0.08−0.12−0.15−0.52−1.40
Dividend / sh $················
Payout %················
ROE %−95.6−81.2−76.1−38.4−56.3−194.8−181.8−168.0−282.6·······
Shares out B0.030.030.020.020.020.020.020.010.010.000.000.070.060.050.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 17 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image